Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 9/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005434 | 1.00 | AGPAT2 (0.48) | AGPAT2ADRB2PTGDR2DHFRSLC9A1 | |
| SCHEMBL5236993 | 0.84 | ADRB2 (0.52) | AGPAT2ADRB2HPGD | |
| SCHEMBL2006306 | 0.84 | ADRB2 (0.52) | AGPAT2ADRB2HPGD | |
| SCHEMBL2784654 | 0.82 | AGPAT2 (0.55) | AGPAT2PTGDR2DHFRSLC9A1HPGD | |
| SCHEMBL5231980 | 0.78 | ADRB2 (0.41) | ADRB2HPGDTSHRMAPT | |
| SCHEMBL2006705 | 0.78 | ADRB2 (0.41) | ADRB2HPGDTSHRMAPT | |
| SCHEMBL12493625 | 0.76 | AGPAT2 (0.52) | AGPAT2PTGDR2DHFRHPGDTSHR | |
| SCHEMBL13877335 | 0.75 | MAPT (0.45) | ADRB2TSHRMAPTLMNATP53 | |
| SCHEMBL8205115 | 0.75 | MAPT (0.45) | ADRB2TSHRMAPTLMNATP53 | |
| SCHEMBL21508081 | 0.74 | KCNH2 (0.44) | AGPAT2SLC9A1HPGDTSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | AGPAT2 2260/4885ADRB2 104/4885PTGDR2 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.